Verona Pharma plc

Verona Pharma — Merger or Acquisition (July 2025)

15 slides from Verona Pharma's merger presentation, Jul 10, 2025

  1. Slide 1: Verona Pharma Employee Town Hall with Merck

    Verona Pharma Employee Town Hall with Merck Thursday, July 10, 2025

  2. Slide 2: Forward-looking statement of Merck & Co., Inc.

    Forward - looking statement of Merck & Co., Inc. This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward - looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are base

  3. Slide 3: Additional information and where to find it

    Additional information and where to find i t In connection with the proposed transaction between Verona Pharma and Merck, Verona Pharma will file with the Securities and Exchange Commission (“SEC”) a proxy statement on Schedule 14A. Additionally, Verona Pharma may file other relevant materials with

  4. Slide 4: Participants in the solicitation

    Participants in the solicitation Verona Pharma, Merck and certain of their directors and executive officers may be deemed to be participants in the solicitati on of proxies from the shareholders of Verona Pharma in connection with the proposed transaction. Information about Verona Pharma’s directors

  5. Slide 5: Today's agenda

    Today’s agenda 5 Welcome Overview of Merck Building on your scientific success Coming together for patients Next steps

  6. Slide 6: Welcome

    6 6 Welcome David Zaccardelli, President and CEO Verona Pharma

  7. Slide 7: Overview of Merck

    7 7 Overview of Merck Rob Davis, Chairman and CEO

  8. Slide 8: We are unified around Our Purpose

    We are unified around Our Purpose We use the power of leading - edge science to save and improve lives around the world “W e try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. " – Georg

  9. Slide 9: Building on your scientific success

    9 9 Building on your scientific success Dean Li, President, Merck Research Laboratories

  10. Slide 10: Together, we will address significant unmet need in COPD

    Together, we will address significant unmet need in COPD 10 Clinical studies provide strong clinical validation for Ohtuvayre as a highly effective treatment for patients with moderate to severe symptomatic COPD Committed to finding the best external science to complement our internal innovation and

  11. Slide 11: Coming together for patients

    11 11 Coming together for patients Jannie Oosthuizen, President, Human Health U.S.

  12. Slide 12: Significant opportunity to benefit patients with COPD

    18 Significant opportunity to benefit patients with COPD 1,2 1. Chen, et al., Int J Chron Obstruct Pulmon Dis. 2018;13:1365 - 1376 2. Phreesia COPD Patient Perceptions Survey 3. Verona Pharma estimates ~8.6M Maintenance Treated COPD Patients 3 ~50% Persistently Symptomatic COPD Patients Regardless o

  13. Slide 13: Next steps

    13 13 Next steps Rob Davis, Chairman and CEO

  14. Slide 14: How we'll work together

    How we’ll work together 14 We are looking forward to working with you We look forward to welcoming the talented Verona Pharma team to Merck. Each of you are critical to maintaining commercial and pipeline momentum. We’ll continue to share along the way We commit to providing updates and information

  15. Slide 15: Thank you!

    Thank you!

Verona Pharma — Merger or Acquisition (July 2025) on 6ix